861 related articles for article (PubMed ID: 25902198)
1. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
[TBL] [Abstract][Full Text] [Related]
2. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
[TBL] [Abstract][Full Text] [Related]
3. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
van Heijl M; Omloo JM; van Berge Henegouwen MI; Hoekstra OS; Boellaard R; Bossuyt PM; Busch OR; Tilanus HW; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Cuesta MA; Ten Kate FJ; Pruim J; van Dekken H; Bergman JJ; Sloof GW; van Lanschot JJ
Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607
[TBL] [Abstract][Full Text] [Related]
4. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.
Konski AA; Cheng JD; Goldberg M; Li T; Maurer A; Yu JQ; Haluszka O; Scott W; Meropol NJ; Cohen SJ; Freedman G; Weiner LM
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):358-63. PubMed ID: 17532577
[TBL] [Abstract][Full Text] [Related]
5. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer.
Jayachandran P; Pai RK; Quon A; Graves E; Krakow TE; La T; Loo BW; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):471-7. PubMed ID: 22381904
[TBL] [Abstract][Full Text] [Related]
6. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma.
Klayton T; Li T; Yu JQ; Keller L; Cheng J; Cohen SJ; Meropol NJ; Scott W; Xu-Welliver M; Konski A
J Gastrointest Cancer; 2012 Dec; 43(4):612-8. PubMed ID: 22777832
[TBL] [Abstract][Full Text] [Related]
7. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
Myslivecek M; Neoral C; Vrba R; Vomackova K; Cincibuch J; Formanek R; Koranda P; Zapletalova J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):171-9. PubMed ID: 22660205
[TBL] [Abstract][Full Text] [Related]
8. Utility of
Arnett ALH; Merrell KW; Macintosh EM; James SE; Nathan MA; Shen KR; Ravi K; Neben Wittich MA; Haddock MG; Hallemeier CL
J Thorac Oncol; 2017 Jan; 12(1):121-128. PubMed ID: 27569732
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography for predicting pathologic response after neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
Chennupati SK; Quon A; Kamaya A; Pai RK; La T; Krakow TE; Graves E; Koong AC; Chang DT
Am J Clin Oncol; 2012 Aug; 35(4):334-9. PubMed ID: 21422989
[TBL] [Abstract][Full Text] [Related]
10. The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation.
Huh JW; Min JJ; Lee JH; Kim HR; Kim YJ
Am J Clin Oncol; 2012 Aug; 35(4):340-4. PubMed ID: 21422901
[TBL] [Abstract][Full Text] [Related]
11. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
[TBL] [Abstract][Full Text] [Related]
12. Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response.
Gerbaudo VH; Killoran JH; Kim CK; Hornick JL; Nowak JA; Enzinger PC; Mamon HJ
Ann Nucl Med; 2018 Apr; 32(3):165-174. PubMed ID: 29332233
[TBL] [Abstract][Full Text] [Related]
13. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
[TBL] [Abstract][Full Text] [Related]
14. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy.
Bruzzi JF; Swisher SG; Truong MT; Munden RF; Hofstetter WL; Macapinlac HA; Correa AM; Mawlawi O; Ajani JA; Komaki RR; Fukami N; Erasmus JJ
Cancer; 2007 Jan; 109(1):125-34. PubMed ID: 17146785
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer.
Song SY; Kim JH; Ryu JS; Lee GH; Kim SB; Park SI; Song HY; Cho KJ; Ahn SD; Lee SW; Shin SS; Choi EK
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1053-9. PubMed ID: 15964705
[TBL] [Abstract][Full Text] [Related]
16. (18)F-FDG-PET/CT in assessing response to neoadjuvant chemoradiotherapy for potentially resectable locally advanced esophageal cancer.
Metser U; Rashidi F; Moshonov H; Wong R; Knox J; Guindi M; Darling G
Ann Nucl Med; 2014 May; 28(4):295-303. PubMed ID: 24474598
[TBL] [Abstract][Full Text] [Related]
17. Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer.
Stiekema J; Vermeulen D; Vegt E; Voncken FE; Aleman BM; Sanders J; Boot H; van Sandick JW
Clin Nucl Med; 2014 Oct; 39(10):862-7. PubMed ID: 25140549
[TBL] [Abstract][Full Text] [Related]
18. Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy.
Tan S; Kligerman S; Chen W; Lu M; Kim G; Feigenberg S; D'Souza WD; Suntharalingam M; Lu W
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1375-82. PubMed ID: 23219566
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.
Levine EA; Farmer MR; Clark P; Mishra G; Ho C; Geisinger KR; Melin SA; Lovato J; Oaks T; Blackstock AW
Ann Surg; 2006 Apr; 243(4):472-8. PubMed ID: 16552197
[TBL] [Abstract][Full Text] [Related]
20. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.
Swisher SG; Erasmus J; Maish M; Correa AM; Macapinlac H; Ajani JA; Cox JD; Komaki RR; Hong D; Lee HK; Putnam JB; Rice DC; Smythe WR; Thai L; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
Cancer; 2004 Oct; 101(8):1776-85. PubMed ID: 15386332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]